Novavax (NVAX) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $4.04. This compares to loss of $3.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -6.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $3.76 per share when it actually produced a loss of $4.75, delivering a surprise of -26.33%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $178.84 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 41.71%. This compares to year-ago revenues of $157.02 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Novavax shares have added about 75.1% since the beginning of the year versus the S&P 500's gain of 24.1%.
精彩评论